Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA/CD19 Dual-Target CAR-T in R/R Multiple Myeloma
NCT04182581Phase 1Unknown
- Sponsor
- Xijing Hospital
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCMA/CD19 dual-target CAR-T cell immunotherapy (Hebei Yanda Ludaopei Hospital) in multiple myeloma (MM), sponsored by Xijing Hospital. Status: unknown.
02
Drugs
BCMA/CD19 dual-target CAR-T cell immunotherapy (Hebei Yanda Ludaopei Hospital)
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04182581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182581.